Cargando…
Therapeutic reduction of ataxin 2 extends lifespan and reduces pathology in TDP-43 mice
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurodegenerative disease characterized by motor neuron loss, leading to paralysis and death 2–5 years following disease onset(1). Nearly all ALS patients contain aggregates of the RNA-binding protein TDP-43 in the brain and spinal cord(2)...
Autores principales: | Becker, Lindsay A., Huang, Brenda, Bieri, Gregor, Ma, Rosanna, Knowles, David A., Jafar-Nejad, Paymaan, Messing, James, Kim, Hong Joo, Soriano, Armand, Auburger, Georg, Pulst, Stefan M., Taylor, J. Paul, Rigo, Frank, Gitler, Aaron D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642042/ https://www.ncbi.nlm.nih.gov/pubmed/28405022 http://dx.doi.org/10.1038/nature22038 |
Ejemplares similares
-
Reduction of nemo-like kinase increases lysosome biogenesis and ameliorates TDP-43–related neurodegeneration
por: Tejwani, Leon, et al.
Publicado: (2023) -
Early activation of cellular stress and death pathways caused by cytoplasmic TDP-43 in the rNLS8 mouse model of ALS and FTD
por: Luan, Wei, et al.
Publicado: (2023) -
Intracellular dynamics of Ataxin-2 in the human brains with normal and frontotemporal lobar degeneration with TDP-43 inclusions
por: Watanabe, Ryohei, et al.
Publicado: (2020) -
Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins
por: Zeballos C, M. Alejandra, et al.
Publicado: (2023) -
Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins
por: Zeballos C., M. Alejandra, et al.
Publicado: (2023)